1 Min Read
Jan 31 (Reuters) - Trillium Therapeutics Inc :
* Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.